Genetic Determinants of Opioids Analgesia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00226564|
Recruitment Status : Completed
First Posted : September 27, 2005
Last Update Posted : October 29, 2008
The response to opioids varies greatly among individuals. Some of these variability is accounted for by genetic factors.
The present study was designed to evaluate the possibility that genetic polymorphism in the gene encoding for mu opioid receptor may explain variability in the response to alfentanil during lithotripsy.
|Condition or disease||Intervention/treatment||Phase|
|Nephrolithiasis||Drug: Alfentanil||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Effect of mu Opioid Receptor Polymorphism on the Response to Alfentanil During Lithotripsy|
|Study Start Date :||August 1997|
- Total alfentanil dose used during the procedure.
- The extent of respiratory depression.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00226564
|Hadassah Medical Organization|
|Principal Investigator:||Yoseph Caraco, MD||Hadassah Medical Organization|